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Abstract
Background: Methylene blue (MB) was the first synthetic antimalarial to be discovered and was used during the
late 19th and early 20th centuries against all types of malaria. MB has been shown to be effective in inhibiting
Plasmodium falciparum in culture, in the mouse model and in rhesus monkeys. MB was also shown to have a
potent ex vivo activity against drug-resistant isolates of P. falciparum and P. vivax. In preclinical studies, MB acted
synergistically with artemisinin derivates and demonstrated a strong effect on gametocyte reduction in P.
falciparum. MB has, thus, been considered a potentially useful partner drug for artemisinin-based combination
therapy (ACT), particularly when elimination is the final goal. The aim of this study was to review the scientific
literature published until early 2017 to summarise existing knowledge on the efficacy and safety of MB in the
treatment of malaria.
Methods: This systematic review followed PRISMA guidelines. Studies reporting on the efficacy and safety of MB
were systematically searched for in relevant electronic databases according to a pre-designed search strategy. The
search (without language restrictions) was limited to studies of humans published until February 2017.
Results: Out of 474 studies retrieved, a total of 22 articles reporting on 21 studies were eligible for analysis. The 21
included studies that reported data on 1504 malaria patients (2/3 were children). Older studies were case series and
reports on MB monotherapy while recent studies were mainly controlled trials of combination regimens. MB was
consistently shown to be highly effective in all endemic areas and demonstrated a strong effect on P. falciparum
gametocyte reduction and synergy with ACT. MB treatment was associated with mild urogenital and gastrointestinal
symptoms as well as blue coloration of urine. In G6PD-deficient African individuals, MB caused a slight but clinically
non-significant haemoglobin reduction.
Conclusions: More studies are needed to define the effects of MB in P. falciparum malaria in areas outside Africa and
against P. vivax malaria. Adding MB to ACT could be a valuable approach for the prevention of resistance development
and for transmission reduction in control and elimination programs.
Systematic review registration: This study is registered at PROSPERO (registration number CRD42017062349).
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Background
Malaria remains the most important parasitic disease in
humans [1]. Combination treatment of malaria has
become the accepted paradigm in malaria control, with
the particular aim of delaying and possibly reversing the
development of drug resistance [2]. Artemisinin-based
combination therapy (ACT) has become the standard
treatment for falciparum malaria in virtually all endemic
regions in the 21st century [3, 4]. However, artemisinin
resistance is emerging in South-East Asia, and there is a
clear need to develop strategies to protect the ACTs [5].
One potentially useful strategy could be to add a third
drug with an independent anti-parasitic activity [6].
Moreover, the World Health Organization recommends
the addition of a gametocytocidal drug such as prima-
quine (PQ) to current ACT regimens for malaria elimin-
ation programs [7].
Methylene blue (MB) is a water-soluble dye, which
has been used for a long time in industry and medi-
cine [8, 9]. The drug is rapidly and widely distributed
throughout the body [10, 11]. The drug is well absorbed
from the gastrointestinal tract and partly monodemethy-
lated to azure B. Maximal plasma concentrations are
reached 2 hours following oral administration, and the
plasma half-life is about 20 h [12]. Renal excretion of MB
and azure B (in oxidised blue or reduced uncoloured
forms) is the main elimination pathway [13, 14].
MB is a registered drug in most countries for various in-
dications, such as the treatment of both acquired and her-
editary methaemoglobinaemia, the prevention of
ifosfamide-induced encephalopathy in human cancer
management, the prevention of urinary tract infections,
the intraoperative visualisation of nerves and endocrine
glands as well as of pathologic fistulae, and the sterilisation
of transfusion blood [9, 15–23]. MB has also been consid-
ered to be effective in priapism, against septic shock
(blocking the NO-dependant guanylate-cyclase) and in
vasoplegic patients after cardiac surgery, and it is under
investigation as an experimental drug against Alzheimer’s
disease [24–28]. MB was the first synthetic antimalarial to
be used, which occurred in a German hospital some
120 years ago [29]. Its global use in malaria endemic areas
is well documented for the late 19th and early 20th cen-
turies [30, 31]. However, it stopped being used after new
synthetic antimalarials were developed [9].
The interest in MB as an antimalarial drug was reacti-
vated when Plasmodium falciparum glutathione reduc-
tase was identified as a new drug target [8, 32–34],
although this concept has been questioned by other ex-
perimental evidence [35]. Like its major catabolite, azure
B, MB is a subversive redox-cycling substrate, and like
4-aminoquinolines, it also interacts with the polymerisa-
tion of haem to hemozoin [34, 36–38]. Indeed, further
but not yet fully understood mechanisms appear to be
involved, which renders the development of resistance to
MB with its multifactorial activity rather unlikely [9, 10].
The development of resistance to MB was proven to be
difficult in vivo [39]. MB has been shown to be effective in
inhibiting P. falciparum in culture, in the mouse model
and in rhesus monkeys [40, 41]. MB was also shown to
have a potent ex vivo activity against drug-resistant
isolates of P. falciparum and P. vivax [42, 43]. In preclin-
ical studies, MB acted synergistically with artemisinin
derivates, but not with chloroquine (CQ), and was shown
to have a strong effect on gametocyte reduction in P.
falciparum [44–48]. MB has, thus, been considered a po-
tentially useful partner drug for ACT, particularly when
elimination is the final goal [49]. The aim of this study
was to review the scientific literature published until early
2017 to summarise existing knowledge on the efficacy and
safety of MB in the treatment of malaria.
Methods
This systematic review follows the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines [50].
Study inclusion and exclusion criteria
All available and accessible data published until 28
February 2017 on the efficacy and/or safety of MB in
the treatment of malaria were considered. Studies
reporting data on MB given to humans of any age as
monotherapy or in combination with other antimalar-
ials and irrespective of drug formulations and sample
size were included. In vitro and animal studies with
MB, reports on the use of MB in humans for indica-
tions that were not malaria and review papers were
excluded.
Search strategy and selection criteria
Standard electronic databases were searched for scien-
tific papers on the subject, but also hand searches were
done in scientific books of major libraries. The following
databases were searched for studies published in any
language: Medline, Embase, BIOSIS, Cochrane Central
Register of Controlled Trials, Cochrane Library, Web of
Science, and the China National Knowledge Infrastruc-
ture and the Chinese Biomedical databases. The search
used combinations of the terms “malaria” and “methy-
lene blue” as both medical subject headings and key or
free text words and included a broad range of deriva-
tions to ensure as wide a search strategy as possible. A
list of the detailed search strategy used is available online
as Additional file 1. We also retrieved and manually
searched articles with relevant titles but an unclear or
no abstract. Bibliographies of reports were searched and
additional relevant references identified and, where ap-
propriate, included in the review.
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Data extraction and analysis
The electronic reports identified were imported into the
reference manager Endnote and duplicates removed. Each
paper was assessed in two phases: first by screening title
and abstract, and then by full-text review to ensure it met
the inclusion criteria. The first assessment was done by
two reviewers (MN and NG). The second assessment was
done by GL and OM. An additional reviewer (AJ) settled
any discordance between the reviewers.
Predetermined study characteristics were defined for
extraction and documentation by two of the investiga-
tors (GL and OM), first independently and then in a
consensus procedure. Reports selected were stratified ac-
cording to study type. The primary outcome was the re-
ported cure rate. Secondary outcomes were fever and
parasite clearance rates, the effect on malaria gameto-
cytes and adverse events (AEs).
Quality appraisal
Two of the investigators (GL and OM) evaluated the
quality of included studies in a consensus procedure.
The risk of bias of randomised controlled trials (RCTs)
was evaluated by the tool described in the Cochrane
Handbook for Systematic Reviews of Interventions [51].
The risk of bias in other controlled studies was evalu-
ated by MINORS, for which 12 methodological items
are reported [52]. Each domain was scored 0 (not re-
ported), 1 (reported but inadequate) or 2 (reported and
adequate). The maximum ideal score was 24.
Quality criteria for case series and case reports were
developed from MINORS and the 2016 Critical Ap-
praisal Checklist of the Joanna Briggs Institute for case
reports and case series [52–54]. Seven methodological
domains were evaluated (score 0 = not reported, score 1
= reported but inadequate or score 2 = reported and ad-
equate). The maximum ideal score was 14. Where ne-
cessary, study authors have been contacted for
clarification. Due to a lack of homogeneity among the
studies, a meta-analysis was not possible.
Results
Study selection
Figure 1 summarises the selection process. After remov-
ing duplicates, the literature search identified 474 re-
cords of which 151 were selected for full text assessment
(Additional file 2). Of these, 129 were excluded leaving
22 publications reporting on 21 studies for data extrac-
tion and further analysis [29, 55–75].
The most common reasons for exclusion were as fol-
lows: the manuscripts were reviews or comments or
guidelines (n = 47), studies were not retrievable despite
exhaustive efforts due to very old date (n = 38), manu-
scripts provided insufficient information (n = 32), pre-
clinical studies (n = 5), MB was not used for treatment
of malaria (n = 4), and patients were not treated with
MB (n = 3).
General study characteristics
The 21 studies included are summarised in Table 1.
They originated from Africa (n = 7), Asia (n = 3), the
Americas (n = 3) and Europe (n = 8) and reported data
on 1504 malaria patients (2/3 were children). The major-
ity of reports were historical studies from around the
year 1900 (n = 15), one was from the year 1949, and the
remaining (n = 5) were published after the year 2000.
The historical studies reported on malaria types diag-
nosed microscopically and/or clinically, which were not
always well specified (of 368 cases, 30 were diagnosed as
quartan malaria, 87 as tertian malaria, 183 as falciparum
malaria, one as a double infection with tertian malaria
and falciparum malaria, and the remaining were not
specified). The more recently conducted controlled trials
reported microscopically well determined outcomes on
falciparum malaria (n = 5) and on vivax malaria (n = 1).
Study designs and MB regimens
Fifteen studies were historical case reports (n = 5) or
case series (n = 10), while six studies were non-
randomised controlled trials (n = 3) or RCTs (n = 3) from
more recent years.
Summaries of treatment regimens are shown in
Table 1. In the historical studies, MB was usually
given in divided doses (e.g. five times per day) of 300–
1000 mg per day in adults and 20–300 mg per day in
children for 3–90 days as daily or interrupted (e.g. a 2-day
pause after several days of treatment) oral monotherapy,
with largely varying follow-up periods [29, 62, 64–67, 69].
In the controlled study on vivax malaria, MB was given to
adults at a dose of 500 mg per day for 14 days in combin-
ation with isopentaquine (IQ) or in combination with IQ
and quinine (Q) [61]. In the very recent RCTs on
falciparum malaria, MB was given to children in various
combination regimens [MB- CQ, MB-amodiaquine (AQ),
MB-artesunate (AS) or MB-AQ-AS] in doses ranging
from 4 mg/kg per day to 24 mg/kg per day, initially as 2–4
divided doses per day, and always for 3 days [56, 58, 60].
The latest dose regimen applied was 15 mg/kg per day in
a single dose over 3 days [55]. In the only recently
conducted MB monotherapy study, MB in adults was ad-
ministrated at a fixed dose of 780 mg per day for 3, 5 or 7
days [59]. In the controlled studies, comparator regimens
were CQ, AS-AQ, IQ and IQ-Q [56, 58, 60, 61].
Quality of included studies
Tables 2, 3 and 4 show the quality assessment of the
studies included. The three RCTs had a low risk for bias
and were consequently considered to be of high quality.
Of the three non-RCTs, the two recently conducted
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studies scored rather high and were, thus, considered of
high quality, while the study from 1949 had a relatively
low quality score. The quality of the case series and case
reports finally included in our review was overall high.
The mean quality score was 10.53, and the majority of
case series and case reports provided a clear description
of malaria treatment and efficacy outcomes. The infor-
mation most frequently missing from case series and re-
ports was study participant characteristics (33.3%, 5/15)
and safety outcomes (26.7%, 4/15).
Efficacy of MB against asexual parasites
In MB monotherapy studies conducted around the year
1900, 337/373 (90%) of malaria cases were reported to
be cured. Reported potential reasons for treatment fail-
ure were: unsuccessful quinine pretreatment (n = 8),
vomiting of treatment (n = 3), low dose of MB (n = 6)
and unknown (n = 19). In a more recent trial, MB mono-
therapy in 60 West African adults with falciparum
malaria (a fixed dose of 780 mg for 3 days) showed a
100% cure rate when MB was given for 7 days compared
to a 85% cure rate when MB was given for a shorter
time period; this difference was close to being statisti-
cally significant [59].
Like MB in the combination treatment, a controlled
study on vivax malaria among US prisoners from 1949
reported a cure rate of 6/9 (67%) for MB plus IQ and of
3/3 (100%) for MB plus IQ plus quinine [61]. In the
recent RCTs among West African children with falcip-
arum malaria, MB-based regimens (n = 391) showed su-
perior efficacy compared to control regimens (n = 207).
In the first trial, the cure rate of MB (4 mg/kg per day)
plus CQ (56%) was slightly but non-significantly higher
compared to that of CQ alone (46%) [58]. A subsequent
dose-finding study demonstrated an improved efficacy
(77%) of MB-CQ when higher doses of MB (12–24 mg/kg
per day) were used [60]. A third study compared the
regimens MB-AQ, MB-AS (MB at 20 mg/kg per day) and
Fig. 1 Selection process of the review. * Original full article not available due to it being very old despite exhaustive searches of all possible
resources including databases and libraries and making contact with journal archivists. † Information was missing on more than three parameters
of the analysis and there was no possibility of getting this from other resources. MB methylene blue, RCT randomised controlled trial
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AS-AQ. The cure rates were 95%, 62% and 82%, respect-
ively, and these differences were statistically significant
[56]. Finally, a trial that compared AS-AQ-MB (MB at
15 mg/kg per day) with AS-AQ produced similar cure
rates in both regimens (80% vs 85%) [55].
Parasite clearance with MB appeared to be rather slow.
In African adults treated with MB monotherapy, 9% were
still parasitaemic on day 3 [59]. In children treated with
MB-CQ or CQ, the median parasite clearance time did
not differ (91.3 and 86.4 h) [58]. In children treated with
MB-AS, only 2% were parasitaemic on day 3, i.e., a signifi-
cantly lower proportion than following treatment with
AS-AQ (5%) or MB-AQ (17%) [56]. The clearance time
for the P. falciparum parasite was non-significantly short-
ened in children receiving AS-AQ-MB compared to the
AS-AQ group (medians 43.7 vs 47.0 h) [55]. Fever was
cleared rapidly in all of these studies without differences
between MB and comparator regimens [55, 56, 58].
Efficacy of MB against gametocytes
Gametocyte clearance following MB-based treatment
was investigated in two RCTs. The first study was a sec-
ondary analysis of data from an RCT in children. Com-
pared to AS-AQ, both MB-containing regimens were
associated with significantly reduced gametocyte carrier
rates during follow-up days 3, 7 and 14 [57]. The second
study, in which post-treatment gametocyte prevalence
was the main outcome variable, demonstrated a signifi-
cantly lower figure in children treated with MB-AS-AQ
compared to AS-AQ on day 7 of follow-up (microscop-
ically, 1% vs 9%; by QT-NASBA, 37% vs 63%) [55].
Safety and acceptability of MB
Treatment of malaria with MB was consistently associ-
ated with green-blue discoloration of urine. AEs
concerning the urogenital system (urethritis) and the
gastrointestinal system (vomiting) were reported to be
associated with MB treatment. These AEs were more
frequently reported with higher doses of MB [65, 66, 69,
75]. Vomiting in children was often associated with the
bitter taste of MB, depending on the type of formulation.
In two RCTs, vomiting in MB-containing regimens
ranged from 24% to 68% [55, 56]. Urethritis was re-
ported in 78% of adults and in 55% of older children
treated with MB, but this symptom was not reported
from RCTs in preschool children [56, 59]. In the
controlled studies, severe adverse events (SAEs) were
rarely reported and none were attributed to MB [60]. In
particular, there were no cases of severe haemolysis asso-
ciated with MB.
Despite some AEs being clearly associated with MB
treatment, one study reported no differences between
study groups in acceptance rates by parents and care-
givers of children [55].
Discussion
This is the first review within the last 100 years to at-
tempt systematically to collect and analyse all the data
that have been published on the effects of MB in the
treatment of human malaria. As MB was used for this
indication globally in the late 19th and early 20th
Table 3 Quality assessment of included non-randomised
controlled trials
Methodological item Score for studiesa
Bountogo et al.
Burkina Faso
(2010) [59]
Meissner et al.
Burkina Faso
(2006) [60]
Alving (1949)
Cited by Baird et al.
(2012) [61]
Clearly stated aim 2 2 1
Inclusion of consecutive patients 2 2 1
Prospective collection of data 2 2 0
End points appropriate to the
aim of the study
1 2 1
Unbiased assessment of the
study end point
2 2 0
Follow-up period appropriate
to the aim of the study
2 2 1
Loss to follow-up less than 5% 2 2 0
Prospective calculation of the
study size
2 2 0
Adequate control group 1 2 1
Contemporary groups 1 1 1
Baseline equivalence of groups 1 2 0
Adequate statistical analyses 2 2 0
Total score 20 23 6
aThe items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported
and adequate). The global ideal score was 24 for comparative studies
Table 2 Quality assessment of included randomised controlled trials
Study:
First Author
Place of study
(Year)
Selection biasa (random
sequence generation)
Performance biasa (blinding of
the participants and personnel)
Detection biasa (blinding
of outcome assessment)
Attribution biasa (incomplete
outcome data)
Reporting biasa
(selective reporting)
Allocation concealment biasa
Coulibaly et al.
Burkina Faso
(2015) [55]
Low Low Low Low Low Low
Zoungrana et al.
Burkina Faso (2008) [56, 57]
Low Low Low Low Low Low
Meissner et al.
Burkina Faso
(2005) [58]
Low Low Low Low Low Low
aAssessed as low, unclear or high risk of bias
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centuries, some early reviews were published at that
time. In 1904, a meta-analysis of 425 malaria cases from
11 publications concluded that MB was effective in 85%
of patients [30].
In the early 20th century, MB was gradually replaced
by new synthetic antimalarials with different characteris-
tics and finally without colouring properties [9]. Scien-
tists at Bayer used MB as the starting point for
systematic antimalarial testing of synthetic compounds.
Thus, the first synthetic drug designed as an antimalar-
ial, pamaquine, was derived from MB [76].
The revival of MB as an antimalarial drug candidate
began in 1995, at the height of the development of
resistance against existing antimalarials, in three biochem-
ical laboratories [32, 35, 38]. A key achievement was the
detection that MB inhibits the glutathione reductase of P.
falciparum [8]. Considerably elevated glutathione levels
were found in CQ-resistant P. falciparum strains, trigger-
ing the hypothesis that combining MB and CQ might
overcome resistance [8]. This was the rationale to start
clinical trials with MB in the early 21st century.
Efficacy of MB against malaria
In our analysis of 15 case reports and case series, 339/373
(91%) of patients were cured, which provides evidence for
the high efficacy of MB monotherapy in the treatment of
malaria. Treatment failures were attributed to previously
unsuccessful quinine treatment, vomiting and a low and/
or short MB dosing regimen, which helps to explain early
controversies on whether quinine or MB was more effect-
ive against malaria [63–65, 77]. Conducted in tropical as
well as in non-tropical areas and including all types of
human malaria, these early studies were of overall good
external validity. Interestingly, the MB dosing schedules
used in these early studies were rather similar to what has
been found to be effective in a MB dose-finding study in
African children as well as in a proof of principle MB
monotherapy study in African adults [59, 60].
In the recent studies, MB was usually given in combin-
ation with other antimalarials and tested in RCTs. In an
area of high CQ resistance, MB-CQ was more effective
than CQ alone but not sufficiently so [58, 60]. Combin-
ing MB with AS, AQ or AS-AQ and increasing MB
doses in these combinations did not lead to a substantial
increase in efficacy [55, 56]. This indicates that the cura-
tive efficacy of MB in eliminating asexual parasitaemia
appears to be limited in the study region of Burkina Faso
compared to the cure rates observed roughly a hundred
years ago in a variety of settings. There is no evidence
for and—because of the lack of drug pressure—no rea-
son to expect that MB resistance has emerged mean-
while. The actual causes of the comparatively lower
efficacy of MB-containing regimens in the recent stud-
ies, thus, remains unclear. Total dosage and a generally
longer treatment period in the older studies might be
relevant, however.
Despite this limitation, other properties of MB are not-
able and promising. Adding MB to an ACT reinforced
the particular beneficial effects of the artemisinins, i.e., it
further accelerated the elimination of asexual P. falcip-
arum parasites and reduced P. falciparum gametocytes
[55–57]. The epidemiological relevance of the latter
observation has recently been confirmed by a phase II
study in Mali, which showed a 100% reduction of
mosquito infectivity by day 7 both with PQ- and MB-
containing drug regimens through membrane feeding
assays [78]. This supports findings from preclinical stud-
ies on an existing synergy between MB and artemisinins
as well as on the very strong effects of MB on P. falcip-
arum gametocyte reduction [41, 44, 45, 79]. Interest-
ingly, the efficacy of MB against gametocytes had been
observed in historical studies [30]. However, further
studies to identify the lowest effective dose for the game-
tocytocidal effect of MB in falciparum malaria should be
conducted.
Safety of MB in malaria treatment
In the historical studies, MB was usually given orally and
often in high doses and for prolonged periods of time,
both in children and in adults, and without reports of
major safety problems. During World War I for ex-
ample, some European soldiers received more than
400 g of MB over several weeks without major side ef-
fects, apart from moderate urogenital symptoms [31].
Brazilian children were reported to tolerate 20–50 mg/
kg per day of MB very well for long periods of time [68].
Also, in the recent RCTs conducted in West Africa, MB
treatment was not associated with SAEs. However, while
MB given orally seems to be largely well tolerated, MB
given intravenously must be applied with caution. Intra-
venous MB is often routinely given as the first-line treat-
ment for acute acquired methemoglobinemia in doses of
1–2 mg/kg, but a dose of 7 mg/kg can lead to severe
gastrointestinal symptoms [9]. Moreover, a dose of
5 mg/kg has been reported to be associated with an al-
tered mental status during parathyroidectomy [80]. For
sheep, the LD50 of MB was found to be 42 mg/kg when
applied intravenously [81].
AEs shown to be associated with MB treatment are
mild gastrointestinal symptoms, which may manifest as
vomiting, and mild urogenital symptoms, which usually
manifest shortly after drug intake. This has consistently
been reported, both in historical studies and in more re-
cently conducted RCTs. Pure MB powder or MB
dissolved in water has a very bitter and metallic taste.
The gastrointestinal symptoms are clearly influenced by
the formulation of MB, which suggests it is better to use
taste-masked formulations. As the World Health
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Organization is now also recommending solid formula-
tions for small children, mini-tablets, which should also
be taste-masked, will be preferred over liquid formula-
tions [82]. MB given with food and with a small amount
of grated nutmeg has consistently been described as be-
ing effective in suppressing the frequently reported
gastrointestinal and urogenital AEs [30, 60, 66]. Finally,
both MB and PQ were recently shown to be well toler-
ated in males in Mali [78].
MB is on the list of drugs potentially dangerous for pa-
tients with G6PD deficiency, but the clinical importance of
this is still controversial [83, 84]. In this review, no associ-
ation between MB and severe haemolysis has been de-
tected. Nevertheless, in a pooled analysis of all recent
studies conducted with MB against falciparum malaria in
West African children (including one unpublished RCT),
small effects were seen. In 844 MB-treated African children,
two patients developed severe anaemia (Hb < 5 g/dL)
during the first days of treatment and both were G6PD de-
ficient. Minimal Hb concentrations following MB treatment
did not significantly differ in children with and without
G6PD deficiency. However, when modelling the Hb time
course, an MB dose-dependent effect of lowering Hb
concentrations was observed for children with a full G6PD
defect (hemi- and homozygous deficiency; prevalence,
10%). The maximal difference compared to non-deficient
peers was estimated as −0.9 g/dl on day 5 of the follow-up,
which is, however, considered to be of limited clinical
relevance [85]. In sub-Saharan Africa, the moderate A
minus type of X-chromosomally inherited G6PD deficiency
(15–25% enzyme activity) dominates and affects 10–25% of
the population. G6PD-deficient red blood cells have in-
creased sensitivity to oxidative stress originating from vari-
ous triggers including antimalarial drugs [86]. Whether or
not MB confers an increased risk in malaria patients with
more severe variants of G6PD deficiency needs to be evalu-
ated in future studies, e.g. in South-East Asia. There are,
however, reports of MB being associated with severe
haemolytic reactions in neonatal G6PD deficiency [87, 88].
Finally, MB at low concentration is a strong inhibitor of
monoamine oxidase A and therefore, should not be given
together with serotonin reuptake inhibitors [89].
Reassuringly and despite the characteristic AE profile,
MB has been well accepted by patients and caregivers of
children in West Africa, which was also supported by an
anthropological study in Burkina Faso [90]. However, the
acceptance of its colouring properties also needs to be
studied in other populations and cultures.
Strengths and limitations
The strength of this review is that it includes all studies
ever conducted with MB or MB-containing regimens in
humans with malaria irrespective of study design and
sample size and irrespective of the language of the report.
Moreover, it can be considered as beneficial that a number
of authors of this review have been the investigators of all
recently conducted studies on this topic. Limitations of
this review are the lower quality of the historical studies
included compared to recent RCTs, the availability of
three reports only in an abbreviated form from other
sources [73, 91, 92] and the non-availability of a number
of studies due to their old age despite extensive searches.
Conclusions
This review shows that MB has substantial antimalarial
activity against all types of malaria in various endemic
areas and, in combination with other antimalarials, against
falciparum malaria in Africa. Although MB alone appears
to act rather slowly against the asexual parasites of P. fal-
ciparum, it shows synergy with the artemisinin compo-
nent in rapidly clearing the parasites and it is very
effective in reducing the gametocytes and consequently
mosquito transmission. MB is usually well tolerated and
accepted with mild and regularly self-limiting gastrointes-
tinal and urogenital symptoms, which are the main AEs.
To avoid vomiting, the drug should be given in a taste-
masked formulation and/or together with food. In histor-
ical studies, nutmeg has been shown to be effective in
moderating the frequent occurrence of urethritis, which
should be evaluated in future studies. Whether the small
effect of MB on the haemoglobin development is of clin-
ical significance needs to be monitored in future large-
scale studies including regions with more severe forms of
G6PD deficiency compared to African populations.
MB appears to be a potential alternative to PQ for re-
ducing post-treatment infectivity in P. falciparum infec-
tions, a useful partner for triple combination therapy
regimens with the goal of protecting the artemisinin
component of the ACT and of reducing the spread of
drug-resistant parasites, and a potentially valuable part-
ner drug for mass drug administration in malaria elimin-
ation programs. Further studies should investigate the
efficacy, safety and community acceptance of different
ACT regimens in combination with MB against falcip-
arum malaria in different areas inside and outside Africa,
while well-designed pilot studies should investigate the
effects of MB and MB-containing combination regimens
as a treatment for vivax malaria.
Additional files
Additional file 1: Search strategy. (DOCX 12 kb)
Additional file 2: A list of all the records screened after duplicates were
removed (N = 474). (PDF 329 kb)
Abbreviations
ACT: Artemisinin-based combination therapy; AE: Adverse event;
AQ: Amodiaquine; AS: Artesunate; CQ: Chloroquine; IQ: Isopentaquine;
Lu et al. BMC Medicine  (2018) 16:59 Page 13 of 16
MB: Methylene blue; PQ: Primaquine; Q: Quinine; RCT: Randomised
controlled trial; SAE: Severe adverse event
Acknowledgements
We thank Dr Olaf Horstick for his helpful comments on the draft paper.
Funding
The project was funded by BASF (Germany) to celebrate its 150th birthday
and to acknowledge that MB was the first product patented by the firm.
BASF was neither involved in the design and conduct of the study nor in
data analysis and interpretation. The paper was written by the authors
without any interference by BASF.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Authors’ contributions
GL and OM designed the study. MN and NG did the initial literature searches.
GL and OM, with support from MN and NG, analysed the data. All authors
contributed to the interpretation of the data and to writing of the paper. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Medical College of Yangzhou University, Yangzhou University, Yangzhou
225001, China. 2Institute of Public Health, Medical School,
Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. 3Department of
Paediatric and Adolescent Medicine, Ulm University, Ulm, Germany. 4Institute
of Tropical Medicine and International Health, Charité-Universitätsmedizin
Berlin, Berlin, Germany.
Received: 20 December 2017 Accepted: 26 March 2018
References
1. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM.
Malaria. Lancet. 2014;383(9918):723–35.
2. Nosten F, Brasseur P. Combination therapy for malaria: the way forward?
Drugs. 2002;62(9):1315–29.
3. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N, International
Artemisinin Study G. Artesunate combinations for treatment of malaria:
meta-analysis. Lancet. 2004;363(9402):9–17.
4. WHO. World malaria report 2016. Geneva: World Health Organization; 2016
5. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin
Resistance in Cambodia 1 Study C. Evidence of artemisinin-resistant malaria
in western Cambodia. N Engl J Med. 2008;359(24):2619–20.
6. White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113(8):1084–92.
7. WHO. Guidelines for the treatment of malaria-3rd edition. Geneva: World
Health Organization; 2015.
8. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, Eubel J, Becker K,
Becher H, Muller O, Zich T, et al. Methylene blue as an antimalarial agent.
Redox Rep. 2003;8(5):272–5.
9. Schirmer RH, Adler H, Pickhardt M, Mandelkow E. Lest we forget you–methylene
blue. Neurobiol Aging. 2011;32(12):2325. e2327-2316
10. Wainwright M, Amaral L. The phenothiazinium chromophore and the
evolution of antimalarial drugs. Tropical Med Int Health. 2005;10(6):501–11.
11. Warth A, Goeppert B, Bopp C, Schirmacher P, Flechtenmacher C, Burhenne J.
Turquoise to dark green organs at autopsy. Virchows Arch. 2009;454(3):341–4.
12. Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O,
Meissner P, Mikus G. High absolute bioavailability of methylene blue given
as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179–89.
13. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II.
Methylene blue–absorption, metabolism, and excretion in man and dog
after oral administration. J Pharm Sci. 1972;61(7):1086–90.
14. Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ
distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol.
2000;56(3):247–50.
15. Mansouri A, Lurie AA. Concise review: methemoglobinemia. Am J Hematol.
1993;42(1):7–12.
16. Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia.
Treatment issues. Drug Saf. 1996;14(6):394–405.
17. Cawein M, Behlen CH 2nd, Lappat EJ, Cohn JE. Hereditary Diaphorase
Deficiency and Methemoglobinemia. Arch Intern Med. 1964;113:578–85.
18. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated
encephalopathy. N Engl J Med. 1995;332(18):1239–40.
19. Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of
ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343(8900):
763–4.
20. Orth K, Ruck A, Stanescu A, Beger HG. Intraluminal treatment of inoperable
oesophageal tumours by intralesional photodynamic therapy with
methylene blue. Lancet. 1995;345(8948):519–20.
21. O'Leary JL, Petty J, Harris AB, Inukai J. Supravital staining of mammalian
brain with intra-arterial methylene blue followed by pressurized oxygen.
Stain Technol. 1968;43(4):197–201.
22. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen
plasma: what is its contribution to blood safety? Transfusion. 2003;43(9):1322–9.
23. Floyd RA, Schneider JE Jr, Dittmer DP. Methylene blue photoinactivation of
RNA viruses. Antivir Res. 2004;61(3):141–51.
24. Van der Horst C, Stuebinger H, Seif C, Melchior D, Martinez-Portillo FJ,
Juenemann KP. Priapism - etiology, pathophysiology and management. Int
Braz J Urol. 2003;29(5):391–400.
25. Juffermans NP, Vervloet MG, Daemen-Gubbels CRG, Binnekade JM, de Jong
M, Groeneveld ABJ. A dose-finding study of methylene blue to inhibit nitric
oxide actions in the hemodynamics of human septic shock. Nitric
Oxide-Biol Ch. 2010;22(4):275–80.
26. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ,
Boullon FJ. Methylene blue reduces mortality and morbidity in vasoplegic
patients after cardiac surgery. Ann Thorac Surg. 2004;77(2):496–9.
27. Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer's disease.
Biochem Pharmacol. 2009;78(8):927–32.
28. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition
of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad
Sci U S A. 1996;93(20):11213–8.
29. Guttmann P, Ehrlich P. Über die wirkung des methylenblau bei malaria.
Berliner Klin Wochenschr. 1891;28:935–56.
30. Wood HC. The use of methylene blue in malarial fevers. Proc Phila Co Med
Soc. 1904;25:281–6.
31. Marshall DG. The "toxicity" of methylene-blue. Lancet. 1920;195(5051):1334.
32. Farber PM, Arscott LD, Williams CH Jr, Becker K, Schirmer RH. Recombinant
Plasmodium falciparum glutathione reductase is inhibited by the
antimalarial dye methylene blue. FEBS Lett. 1998;422(3):311–4.
33. Sarma GN, Savvides SN, Becker K, Schirmer M, Schirmer RH, Karplus
PA. Glutathione reductase of the malarial parasite Plasmodium
falciparum: crystal structure and inhibitor development. J Mol Biol.
2003;328(4):893–907.
34. Buchholz K, Schirmer RH, Eubel JK, Akoachere MB, Dandekar T, Becker K,
Gromer S. Interactions of methylene blue with human disulfide reductases
and their orthologues from Plasmodium falciparum. Antimicrob Agents
Chemother. 2008;52(1):183–91.
35. Pastrana-Mena R, Dinglasan RR, Franke-Fayard B, Vega-Rodriguez J, Fuentes-
Caraballo M, Baerga-Ortiz A, Coppens I, Jacobs-Lorena M, Janse CJ, Serrano
AE. Glutathione reductase-null malaria parasites have normal blood stage
growth but arrest during development in the mosquito. J Biol Chem. 2010;
285(35):27045–56.
36. Atamna H, Krugliak M, Shalmiev G, Deharo E, Pescarmona G, Ginsburg
H. Mode of antimalarial effect of methylene blue and some of its
analogues on Plasmodium falciparum in culture and their inhibition of
P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem Pharmacol.
1996;51(5):693–700.
37. Kanzok SM, Schirmer RH, Turbachova I, Iozef R, Becker K. The thioredoxin
system of the malaria parasite Plasmodium falciparum. Glutathione
reduction revisited. J Biol Chem. 2000;275(51):40180–6.
Lu et al. BMC Medicine  (2018) 16:59 Page 14 of 16
38. Davioud-Charvet E, Delarue S, Biot C, Schwobel B, Boehme CC, Mussigbrodt
A, Maes L, Sergheraert C, Grellier P, Schirmer RH, et al. A prodrug form of a
Plasmodium falciparum glutathione reductase inhibitor conjugated with a
4-anilinoquinoline. J Med Chem. 2001;44(24):4268–76.
39. Thurston JP. The chemotherapy of Plasmodium berghei. I. Resistance to
drugs. Parasitology. 1953;43(3–4):246–52.
40. Vennerstrom JL, Makler MT, Angerhofer CK, Williams JA. Antimalarial dyes
revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob Agents
Chemother. 1995;39(12):2671–7.
41. Ohrt C, Li Q, Obaldia N, Im-Erbsin R, Xie L, Berman J. Efficacy of intravenous
methylene blue, intravenous artesunate, and their combination in preclinical
models of malaria. Malar J. 2014;13:415.
42. Pascual A, Henry M, Briolant S, Charras S, Baret E, Amalvict R, Huyghues d,
Etages E, Feraud M, Rogier C, Pradines B. In vitro activity of Proveblue
(methylene blue) on Plasmodium falciparum strains resistant to standard
antimalarial drugs. Antimicrob Agents Chemother. 2011;55(5):2472–4.
43. Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Trianty L,
Kenangalem E, Noviyanti R, Campo B, Poespoprodjo JR, et al. Potent Ex Vivo
Activity of Naphthoquine and Methylene Blue against Drug-Resistant
Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.
Antimicrob Agents Chemother. 2015;59(10):6117–24.
44. Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer RH,
Becker K. In vitro assessment of methylene blue on chloroquine-sensitive
and -resistant Plasmodium falciparum strains reveals synergistic action with
artemisinins. Antimicrob Agents Chemother. 2005;49(11):4592–7.
45. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG,
Richman A, Sim BK, Lee MC, Hoffman SL, et al. Quantitative assessment
of Plasmodium falciparum sexual development reveals potent
transmission-blocking activity by methylene blue. Proc Natl Acad Sci U
S A. 2011;108(47):E1214–23.
46. Garavito G, Bertani S, Rincon J, Maurel S, Monje MC, Landau I, Valentin A,
Deharo E. Blood schizontocidal activity of methylene blue in combination with
antimalarials against Plasmodium falciparum. Parasite. 2007;14(2):135–40.
47. Haynes RK, Cheu KW, Li KY, Tang MM, Wong HN, Chen MJ, Guo ZF, Guo ZH,
Coghi P, Monti D. A partial convergence in action of methylene blue and
artemisinins: antagonism with chloroquine, a reversal with verapamil, and
an insight into the antimalarial activity of chloroquine. ChemMedChem.
2011;6(9):1603–15.
48. Garavito G, Bertani S, Quiliano M, Valentin A, Aldana I, Deharo E. The in vivo
antimalarial activity of methylene blue combined with pyrimethamine,
chloroquine and quinine. Mem Inst Oswaldo Cruz. 2012;107(6):820–3.
49. Müller O, Sie A, Meissner P, Schirmer RH, Kouyate B. Artemisinin resistance
on the Thai-Cambodian border. Lancet. 2009;374(9699):1419.
50. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke
M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
51. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J,
Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration's tool for
assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
52. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J.
Methodological index for non-randomized studies (minors): development
and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.
53. Critical appraisal tools-checklist for case reports. http://joannabriggs.org/
assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Case_
Reports2017.pdf.
54. Critical appraisal tools-checklist for case series. http://joannabriggs.org/
assets/docs/critical-appraisal-tools/JBI_Critical_Appraisal-Checklist_for_Case_
Series2017.pdf.
55. Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebie E, Klose C, Kieser M,
Berens-Riha N, Wieser A, Sirima SB, et al. Efficacy and safety of triple
combination therapy with artesunate-amodiaquine-methylene blue for
falciparum malaria in children: a randomized controlled trial in Burkina Faso.
J Infect Dis. 2015;211(5):689–97.
56. Zoungrana A, Coulibaly B, Sie A, Walter-Sack I, Mockenhaupt FP, Kouyate B,
Schirmer RH, Klose C, Mansmann U, Meissner P, et al. Safety and efficacy of
methylene blue combined with artesunate or amodiaquine for
uncomplicated falciparum malaria: a randomized controlled trial from
Burkina Faso. PLoS One. 2008;3(2):e1630.
57. Coulibaly B, Zoungrana A, Mockenhaupt FP, Schirmer RH, Klose C,
Mansmann U, Meissner PE, Muller O. Strong gametocytocidal effect of
methylene blue-based combination therapy against falciparum malaria: a
randomised controlled trial. PLoS One. 2009;4(5):e5318.
58. Meissner PE, Mandi G, Witte S, Coulibaly B, Mansmann U, Rengelshausen J,
Schiek W, Jahn A, Sanon M, Tapsoba T, et al. Safety of the methylene blue
plus chloroquine combination in the treatment of uncomplicated
falciparum malaria in young children of Burkina Faso [ISRCTN27290841].
Malar J. 2005;4:45.
59. Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U,
Mockenhaupt FP, Burhenne J, Mikus G, Walter-Sack I, Schirmer RH, et al.
Efficacy of methylene blue monotherapy in semi-immune adults with
uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Tropical
Med Int Health. 2010;15(6):713–7.
60. Meissner PE, Mandi G, Coulibaly B, Witte S, Tapsoba T, Mansmann U,
Rengelshausen J, Schiek W, Jahn A, Walter-Sack I, et al. Methylene blue for
malaria in Africa: results from a dose-finding study in combination with
chloroquine. Malar J. 2006;5:84.
61. Baird KJ, Maguire JD, Price RN. Diagnosis and treatment of Plasmodium
vivax malaria. Adv Parasitol. 2012;80:203–70.
62. Mayer M. Über die Wirkung von Methylenblau bei Malaria quartana.
Deutsch Med Wochenschrift. 1919;45:1052–3.
63. Panse O. Schwarzwasserfieber. Aus dem Gouvernementskrankenhaus Taga,
Deutsch-Ostafrika. Veit & Comp: Leipzig; 1902.
64. Glogner M. Ein Beitrag zur Beurtheilung der Malaria Rezidive und ihrer
Behandlung. Berlin: Springer; 1900.
65. Ollwig D. Ein Beitrag zur Behandlung der Malaria mit Methylenblau. Z Hyg.
1899;31(31):318–36.
66. Cardamatis JP. 275 klinische Beobachtungen über das Methylenblau.
Deutsche Med Wochenschrift Ther Beilage. 1898;2(9):9–10.
67. Röttger W. Ein Beitrag zur Behandlung der Malaria mit Methylenblau. Kiel:
University Kiel; 1895.
68. Ferreira MC. Sur l'emploi du bleu de méthylène dans la malaria infantile.
Ther Medico-Chirugicale. 1893;124:488–525.
69. Parenski S, Blatteis S. Über das Methylenblau bei Malaria. Ther Monatshefte.
1893;7:16–9.
70. Thayer WS. On the Value of methylene blue in malarial fever. Bull Johns
Hopkins Hosp. 1892;2(22):49–53.
71. Mühlens P, Kirschbaum W. Parasitologische und klinische Beobachtungen
bei künstlichen Malaria und Recurrensübertragungen. Z Hyg Infekt.
1921;94:1–28.
72. Atkinson JM. Ocimum Viride and Malaria. Lancet. 1903;162(4169):265–6.
73. Sivers R. Finska Läkaresällskapets Handlingar. 1901;43:857.
74. Merck E. Merck's Wissenschaftliche Abhandlungen aus den Gebieten der
Pharmakotherapie, Pharmazie und verwandter Disziplinen-Anilinfarben in
der Therapie. Darmstadt: Darmstadt; 1922.
75. Anonymous. Über Methylenblau. Dtsch Med Wochenschr. 1893;19(1):23.
76. Krafts K, Hempelmann E, Skorska-Stania A. From methylene blue to
chloroquine: a brief review of the development of an antimalarial therapy.
Parasitol Res. 2012;111(1):1–6.
77. Kaufmann P. Ueber die Wirkung des Methylenblau bei Malaria. Dtsch Med
Wochenschr. 1919;49:1365.
78. Dicko A, Roh ME, Diawara H, Mahamar A, Soumare HM, Lanke K,
Bradley J, Sanogo K, Kone DT, Diarra K, et al. Efficacy and safety of
primaquine and methylene blue for prevention of Plasmodium
falciparum transmission in Mali: a phase 2, single-blind, randomised
controlled trial. Lancet Infect Dis. 2018. https://doi.org/10.1016/S1473-
3099(18)30044-6. Epub ahead of print.
79. Siciliano G, Santha Kumar TR, Bona R, Camarda G, Calabretta MM, Cevenini
L, Davioud-Charvet E, Becker K, Cara A, Fidock DA, et al. A high susceptibility
to redox imbalance of the transmissible stages of Plasmodium falciparum
revealed with a luciferase-based mature gametocyte assay. Mol Microbiol.
2017;104(2):306–18.
80. Kahn M, North A, Chadwick D. Prolonged postoperative altered mental
status after methylene blue infusion during parathyroidectomy: a case
report and review of literature. Ann R Coll Surg Engl. 2007;89(2):W9–W11.
81. Burrows GE. Methylene blue: effects and disposition in sheep. J Vet
Pharmacol Ther. 1984;7(3):225–31.
82. Orubu ES, Tuleu C. Medicines for children: flexible solid oral formulations.
Bull World Health Organ. 2017;95(3):238–40.
83. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J,
Beig S, Berkovitch M. Medications and glucose-6-phosphate dehydrogenase
deficiency: an evidence-based review. Drug Saf. 2010;33(9):713–26.
Lu et al. BMC Medicine  (2018) 16:59 Page 15 of 16
84. Müller O, Meissner P, Mansmann U. Glucose-6-phosphate dehydrogenase
deficiency and safety of methylene blue. Drug Saf. 2012;35(1):85. author
reply 85-86.
85. Müller O, Mockenhaupt FP, Marks B, Meissner P, Coulibaly B, Kuhnert R,
Buchner H, Schirmer RH, Walter-Sack I, Sie A, et al. Haemolysis risk in
methylene blue treatment of G6PD-sufficient and G6PD-deficient West-
African children with uncomplicated falciparum malaria: a synopsis of four
RCTs. Pharmacoepidem Dr S. 2013;22(4):376–85.
86. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency.
Lancet. 2008;371(9606):64–74.
87. Gauthier TW. Methylene blue-induced hyperbilirubinemia in neonatal
glucose-6-phosphate dehydrogenase (G6PD) deficiency. J Matern Fetal Med.
2000;9(4):252–4.
88. Kirsch I, Cohen H. Heinz body hemlytic anemia from the use of methylene
blue in neonates. J Pediatr. 1980;96(2):276–8.
89. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity:
inhibition of monoamine oxidase A (MAO A) confirms a theoretical
prediction. Br J Pharmacol. 2007;152(6):946–51.
90. Sanon S, Ollivier E, Azas N, Mahiou V, Gasquet M, Ouattara CT, Nebie I,
Traore AS, Esposito F, Balansard G, et al. Ethnobotanical survey and in vitro
antiplasmodial activity of plants used in traditional medicine in Burkina
Faso. J Ethnopharmacol. 2003;86(2–3):143–7.
91. Trintignan. Du bleu de methylene dans le paludisme et dans la
blenhorragie. Bull Med Paris. 1892;46:943–4.
92. Alving AS, Eichelberger L, Arnold JJE. The clinical testing of antimalarial
drugs at Stateville Penitentiary. Semi-Annual Report 1948–49 1949, NIH
Malaria Report NO. 87. (USPHS Antimalarial Grant No.RG 198).
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lu et al. BMC Medicine  (2018) 16:59 Page 16 of 16
